Amazon's new headquarters near Washington DC could elevate Jeff Bezos’ legacy to something far greater than being remembered as the guy that wrecked retail. Read More

Our review of clinical-stage medical cannabis companies continues, with a fledgling biotech that's generating especially keen interest on Wall Street. Is Cara a future bonanza... or short-term fad? Read More

We spotlight Intec Pharma, its rivals, and whether the stock is overpriced or underpriced. Is this Israel-based biotech on the verge of launching blockbuster new drugs? Read More

Marie Kondo's famous book on cleaning out your closet contains some helpful hints that are easily applied to your portfolio. Use this mid-winter bounce to clean out your stocks. Read More

An examination of this popular biotech stock, its rivals, whether it's overpriced or underpriced, and a prediction for its prospects in 2019. Read More

Zynerba Pharmaceuticals is a fledgling, small-cap maker of cannabis-based drugs. The stock has attracted considerable media interest, but is it too risky? We sift through the hype to examine the fundamentals. Read More

Electric vehicle maker Tesla announced earnings last week. The earnings call implies that the company faces a challenging road ahead. Read More

This maker of cannabis-infused medical treatments is a pre-clinical stage biotech with a small market cap. As such, it's a dangerous stock. But do the opportunities outweigh the risks? Read More

An examination of a marijuana "infrastructure play," its rivals, whether it's overpriced or underpriced, and a prediction for the stock in 2019. Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More